Adding docetaxel to standard treatment can prolong prostate cancer-specific survival in patients with nonmetastatic prostate cancer with specific features. Adding docetaxel to standard treatment can ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 best stocks to invest in during a recession. On February 26, 2026, Johnson & Johnson (NYSE:JNJ) provided an update, reporting promising Phase 1b data for ...

Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Docetaxel is a standard treatment for metastatic castration-resistant prostate ...

Survival curves for men treated with and without add-on docetaxel converged with longer follow-up. Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized ...

Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study. Patients with prostate ...

Philadelphia, November 12, 2024 – The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from ...

A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window or on the link ...

Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with ...

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.